Can Intraperitoneal Paclitaxel Improve OS in Gastric Cancer?
A recent study found that adding intraperitoneal paclitaxel to standard treatment significantly improves overall survival in patients with gastric cancer and peritoneal metastasis. The median survival increased to 19.4 months compared to 13.9 months with the standard treatment alone. This approach also enhanced progression-free survival and conversion surgery rates without a rise in severe adverse events.
- ▪Intraperitoneal paclitaxel improved median overall survival to 19.4 months compared to 13.9 months for standard treatment.
- ▪The study involved 222 adults with gastric cancer and peritoneal metastasis, randomized to receive either treatment regimen.
- ▪Patients receiving intraperitoneal paclitaxel had a higher conversion surgery rate of 50.7% compared to 35.1% in the standard group.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Adding intraperitoneal paclitaxel to intravenous paclitaxel plus oral S-1 improved overall survival in patients with gastric cancer and peritoneal metastasis, extending median survival to 19.4 months compared with 13.9 months for intravenous paclitaxel plus S-1 alone. The intraperitoneal paclitaxel approach also improved progression-free survival and conversion surgery rates without increasing the rates of severe adverse events.METHODOLOGY:Gastric cancer with peritoneal metastasis has a poor prognosis, with prior studies reporting median overall survival of roughly 5-11 months with systemic therapy.Researchers conducted a multicenter, open-label, randomized phase 3 superiority trial (DRAGON-01) at nine hospitals in China to assess whether adding intraperitoneal paclitaxel to…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
